In vitrosynergy of colistin combinations against extensively drug-resistantAcinetobacter baumanniiproducing OXA-23 carbapenemase
Authors:
- 22 April 2016
- journal article
- Published by Maney Publishing in Journal of Chemotherapy
- Vol. 28 (3) , 159-163
Abstract
Fifty extensively drug-resistant Acinetobacter baumannii (XDRAB) were isolated from patients. The chequerboard microdilution method was used to determine the in vitro activities of five colistin (COL)-based combinations including COL+fosfomycin (FOS), COL+rifampicin (RIF), COL+imipenem (IMP), COL+sulbactam (SUP) and COL+levofloxacin (LVX). The synergistic activity was evaluated by the fractional inhibitory concentration index (FICI). According to our results, the combination of COL was synergistic with FOS, RIF, IMP, SUP and LVX with the ratios of 50, 72, 88, 92 and 64%, respectively. When combined with COL, the other five agents showed increased antimicrobial activities. In addition, two of the combinations, COL+RIF and COL+IMP, were more active than the combinations of COL+FOS, COL+SUP and COL+LVX. More importantly, these combination regimens could exert synergistic effects at the sub-minimum inhibitory concentration (MIC) levels against XDRAB strains.Keywords
This publication has 23 references indexed in Scilit:
- Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii InfectionsAntimicrobial Agents and Chemotherapy, 2014
- In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumanniiThe Journal of Antibiotics, 2014
- Efficacy of Sulbactam and Its Combination with Imipenem, Colistin and Tigecycline in an Experimental Model of Carbapenem-Resistant Acinetobacter baumannii SepsisChemotherapy, 2013
- Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumanniiDrug Resistance Updates, 2012
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of PatientsAntimicrobial Agents and Chemotherapy, 2011
- In Vitro Double and Triple Bactericidal Activities of Doripenem, Polymyxin B, and Rifampin against Multidrug-Resistant Acinetobacter baumannii , Pseudomonas aeruginosa , Klebsiella pneumoniae , and Escherichia coliAntimicrobial Agents and Chemotherapy, 2010
- Acinetobacter baumannii:an emerging multidrug-resistant threatExpert Review of Anti-infective Therapy, 2008
- Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequencesJournal of Hospital Infection, 2007
- Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsThe Lancet Infectious Diseases, 2006
- Synergy, antagonism, and what the chequerboard puts between themJournal of Antimicrobial Chemotherapy, 2003